Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Review: side effects of approved molecular targeted therapies in solid cancers Widakowich C; de Castro G Jr; de Azambuja E; Dinh P; Awada AOncologist 2007[Dec]; 12 (12): 1443-55Major advances have been achieved in the field of biologically based therapies for cancer in the last few years, and some of the recently approved molecular-targeted therapies are now being used in daily clinical practice. These molecular targets are also expressed in normal cells, which explains the different grades of toxicity, resulting from the disruption of normal cellular function. In general, targeted molecular therapies have good toxicity profiles, but some patients are exquisitely sensitive to these drugs and can develop particular and severe toxicities. In this article, we review the toxicity and safety of various small molecules and monoclonal antibodies used in solid tumors, with discussion of the pathophysiology, correlation with response, and strategies for prevention and management.|*Drug Delivery Systems[MESH]|Angiogenesis Inhibitors/adverse effects[MESH]|Antibodies, Monoclonal/adverse effects[MESH]|Antineoplastic Agents/*adverse effects[MESH]|ErbB Receptors/antagonists & inhibitors[MESH]|Humans[MESH]|Neoplasms/*drug therapy[MESH]|Protein Kinase Inhibitors/adverse effects[MESH]|Receptor, ErbB-2/antagonists & inhibitors[MESH] |